ArticleGut and liver2023
Effective Eradication Regimen and Duration According to the Clarithromycin Susceptibility of
Article in Gut and liver, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- [Evidence-Based Guidelines for the Diagnosis and Treatment ofThe Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2026Guideline
- Guideline
- Bismuth-Based Quadruple Therapy as First-Line Treatment for Clarithromycin-ResistantGut and liver · 2024Trial
- Evidence-Based Guidelines for the Diagnosis and Treatment of Helicobacter pylori Infection in Korea: 2025 Revised Edition.The Korean journal of helicobacter and upper gastrointestinal research · 2026Review
- Clinical applications and methodology updates in HLA typing.BMC immunology · 2026Review
- Concomitant Versus Tailored Therapy Based on Antibiotic Resistance Profiles forJGH open : an open access journal of gastroenterology and hepatology · 2025Review
- Tegoprazan-Amoxicillin Dual Therapy for Clarithromycin-ResistantMicroorganisms · 2025Article
- Tailored therapy guided by genotypic resistance from gastric mucosa samples in the first-line treatment ofTherapeutic advances in gastroenterology · 2025Article
- Can Patients with Clarithromycin-ResistantGut and liver · 2024Article
- Efficacy of 7-day Tailored Therapy forThe Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2023Article
- Considering the Long-Conflicting Topic of Empirical or NonconventionalGut and liver · 2023Article
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
Abstract
Background/Aims: Dual priming oligonucleotide-based multiplex polymerase chain reaction (DPO-PCR) has recently been used for both the detection of Methods: We retrospectively analyzed the electronic medical records of 184 patients who, between September 2019 and December 2020, received eradication therapy following detection of Results: In the clarithromycin susceptible group, per-protocol analyses showed eradication rates of 87.5% (42/48; 95% confidence interval [CI], 77.1% to 95.8%) for 7-day therapy and 87.2% (41/47; 95% CI, 78.7% to 95.7%) for 14-day therapy (p=0.969). The eradication rates in the clarithromycin resistance group were 91.4% (32/35; 95% CI, 80.0% to 100.0%) for 7-day therapy and 90.3% (28/31; 95% CI, 77.4% to 100.0%) for 14-day therapy (p=0.876). There was no significant difference in the eradication rates, patient compliance, or rate of adverse events between the 7- and 14-day therapies for both groups. Conclusions: Compared to the 14-day therapy, 7-day eradication therapy is sufficient after DPO-PCR-based clarithromycin susceptibility testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.